Clinical Trial: A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07850752) titled 'A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy' on Sept. 23.

Brief Summary: This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of disease progression.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: IgA Nephropathy (IgAN)

Intervention: BIOLOGICAL: zigakibart

Solution for injection via PFS-NSD

DRUG: atrasentan

Tablet

DRUG: Placebo

Tablet

Recruitment Status: NOT_YET_RECRUITING...